The Impact of Financial Determinants On Bank Deposits Using ARDL Model

The purpose of this research is to quantify the impact of macroeconomic factors on Jordanian bank deposits in the context of the CoVD-19 epidemic. The annual data are collected between 1980 and 2020. The novel Autoregressive distributed lag (ARDL) model is suggested to evaluate the link between bank deposits and macroeconomic factors. The findings of Grangers causality test indicate that there is a one-way causal link between deposits and macroeconomic factors. Moreover, the study shows no causal link between financial shocks and bank deposits. In addition, the border test investigates the existence of a long-term equilibrium between variables. To attain long-term equilibrium, the imbalance in the short-term equilibrium is adjusted at a rate of 11.6%. Based on the Theil test, the new model is suitable for econometric difficulties and predictability

Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males

The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). Twenty-four healthy male subjects were randomized to one of two cohorts. All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. Rifabutin did not significantly affect amprenavir's pharmacokinetics. Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. Amprenavir decreased the results of the ERMBT by 83%. The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. Amprenavir plus rifampin was well tolerated. Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT